These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 17572787)

  • 21. Acute neuropsychological effects of methylphenidate in stimulant drug-naïve boys with ADHD II--broader executive and non-executive domains.
    Rhodes SM; Coghill DR; Matthews K
    J Child Psychol Psychiatry; 2006 Nov; 47(11):1184-94. PubMed ID: 17076758
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effectiveness of oral osmotic-methylphenidate in treatment of attention deficit hyperactivity disorder in children].
    Pan XX; Ma HW; Wan B; Dai XM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Aug; 10(4):471-4. PubMed ID: 18706164
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A head-to-head randomized clinical trial of methylphenidate and atomoxetine treatment for executive function in adults with attention-deficit hyperactivity disorder.
    Ni HC; Shang CY; Gau SS; Lin YJ; Huang HC; Yang LK
    Int J Neuropsychopharmacol; 2013 Oct; 16(9):1959-73. PubMed ID: 23672818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of MPH-OROS on the organizational, time management, and planning behaviors of children with ADHD.
    Abikoff H; Nissley-Tsiopinis J; Gallagher R; Zambenedetti M; Seyffert M; Boorady R; McCarthy J
    J Am Acad Child Adolesc Psychiatry; 2009 Feb; 48(2):166-75. PubMed ID: 19127171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI; Hong SD; Kim SY; Kim EJ; Kim JH; Kim JH; Park MK; Park S; Park JH; Oh EY; Lim TS; Cheong S; Cho IH; Choi JW
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan; 31(1):210-6. PubMed ID: 17046131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive Improvement of Attention and Inhibition in the Late Afternoon in Children With Attention-Deficit Hyperactivity Disorder (ADHD) Treated With Osmotic-Release Oral System Methylphenidate.
    Slama H; Fery P; Verheulpen D; Vanzeveren N; Van Bogaert P
    J Child Neurol; 2015 Jul; 30(8):1000-9. PubMed ID: 25296928
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of methylphenidate on Stroop Color-Word task performance in children with attention deficit hyperactivity disorder.
    Langleben DD; Monterosso J; Elman I; Ash B; Krikorian G; Austin G
    Psychiatry Res; 2006 Mar; 141(3):315-20. PubMed ID: 16516306
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J; Yang H; Cheng D; Cai X; Signorovitch J; Xie J; Erder MH
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exploring the impact of once-daily OROS® methylphenidate (MPH) on symptoms and quality of life in children and adolescents with ADHD transitioning from immediate-release MPH.
    Kordon A; Stollhoff K; Niederkirchner K; Mattejat F; Rettig K; Schäuble B
    Postgrad Med; 2011 Sep; 123(5):27-38. PubMed ID: 21904084
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Attention-deficit/hyperactivity disorder: the impact of methylphenidate on working memory, inhibition capacity and mental flexibility.
    Bolfer C; Pacheco SP; Tsunemi MH; Carreira WS; Casella BB; Casella EB
    Arq Neuropsiquiatr; 2017 Apr; 75(4):204-208. PubMed ID: 28489138
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M; Weiss M; Swanson J; Wang J; Prinzo RS; Binder CE
    Can J Clin Pharmacol; 2006; 13(1):e50-62. PubMed ID: 16456216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Executive Function Training for Children with Attention Deficit Hyperactivity Disorder.
    Shuai L; Daley D; Wang YF; Zhang JS; Kong YT; Tan X; Ji N
    Chin Med J (Engl); 2017 Mar; 130(5):549-558. PubMed ID: 28229986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder.
    Cox DJ; Merkel RL; Moore M; Thorndike F; Muller C; Kovatchev B
    Pediatrics; 2006 Sep; 118(3):e704-10. PubMed ID: 16950962
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are stimulants effective in the treatment of executive function deficits? Results from a randomized double blind study of OROS-methylphenidate in adults with ADHD.
    Biederman J; Mick E; Fried R; Wilner N; Spencer TJ; Faraone SV
    Eur Neuropsychopharmacol; 2011 Jul; 21(7):508-15. PubMed ID: 21303732
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relationship between symptomatic and functional changes of Korean children and adolescents with attention-deficit/hyperactivity disorder treated with osmotic-controlled release oral delivery system-methylphenidate.
    Kim E; Cheon KA; Joung YS; Kim JY; Song DH
    Clin Neuropharmacol; 2015; 38(1):30-5. PubMed ID: 25580917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate-osmotic-controlled release oral delivery system treatment reduces parenting stress in parents of children and adolescents with attention-deficit/hyperactivity disorder.
    Hwang JW; Kim B; Kim Y; Kim TH; Seo WS; Shin DW; Woo YJ; Yoo H; Lee JS; Lee JH; Lim MH; Chung YC; Jung CH; Yoo HK
    Hum Psychopharmacol; 2013 Nov; 28(6):600-7. PubMed ID: 24519694
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Neuropsychological assessment of the effectiveness of OROS-methylphenidate in attention deficit hyperactivity disorder].
    Rubio-Morell B; Martín-González R; Herreros-Rodríguez O; González-Pérez P; Hernández-Exposito S; Quintero-Fuentes I; Gracia-Marco R
    Rev Neurol; 2008 May 16-31; 46(10):602-8. PubMed ID: 18465700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity Disorder.
    Golubchik P; Kodesh A; Weizman A
    Clin Neuropharmacol; 2017; 40(1):11-15. PubMed ID: 27879551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Naturalistic exploration of the effect of osmotic release oral system-methylphenidate on remission rate and functional improvement in Taiwanese children with attention-deficit-hyperactivity disorder.
    Tzang RF; Wang YC; Yeh CB; Hsu CD; Liang HY; Yang PC; Liu HJ; Huang YS; Cheng H; Hsu YC; Liu SI; Pan CH; Huang YF; Huang CF; Wu YY; Huang YH; Liu HC; Chang HL
    Psychiatry Clin Neurosci; 2012 Feb; 66(1):53-63. PubMed ID: 22250610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.